









Markets
/
Stocks
/
nasdaq-eldn
/

Eledon Pharmaceuticals Inc

ELDN

2.190USD

+0.220+11.17%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

131.14MMarket Cap

8.03P/E TTM



Eledon Pharmaceuticals Inc

2.190

+0.220+11.17%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Eledon Pharmaceuticals Inc

Currency: USD Updated: 2026-02-06

Key Insights

Eledon Pharmaceuticals Inc's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 115 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 8.00.In the medium term, the stock price is expected to remain stable.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Eledon Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

115 / 392

Overall Ranking

249 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Eledon Pharmaceuticals Inc Highlights

StrengthsRisks

Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.

Overvalued

The company’s latest PE is 8.03, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 40.57M shares, increasing 10.51% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 349.20K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.33.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

8.000

Target Price

+306.09%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Eledon Pharmaceuticals Inc is 5.85, ranking 318 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.85

Change



Financials

2.04

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

9.42

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Eledon Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Eledon Pharmaceuticals Inc is 6.46, ranking 276 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is 8.03, which is 4.11% below the recent high of 8.36 and 1114.20% above the recent low of -81.45.

Score

Industry at a Glance

Previous score

6.46

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 115/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Eledon Pharmaceuticals Inc is 8.57, ranking 96 out of 392 in the Biotechnology & Medical Research industry. The average price target is 8.50, with a high of 12.00 and a low of 4.00.

Score

Industry at a Glance

Previous score

8.57

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

8.000

Target Price

+306.09%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Eledon Pharmaceuticals Inc

ELDN

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Eledon Pharmaceuticals Inc is 8.93, ranking 47 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 2.45 and the support level at 1.81, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.12

Change

1.81

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.028

Neutral

RSI(14)

57.484

Neutral

STOCH(KDJ)(9,3,3)

44.425

Neutral

ATR(14)

0.145

Low Volatility

CCI(14)

-87.463

Neutral

Williams %R

37.333

Buy

TRIX(12,20)

0.996

Sell

StochRSI(14)

49.579

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

2.160

Buy

MA10

2.169

Buy

MA20

2.115

Buy

MA50

1.809

Buy

MA100

2.306

Sell

MA200

2.654

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Eledon Pharmaceuticals Inc is 5.00, ranking 139 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 62.44%, representing a quarter-over-quarter decrease of 20.21%. The largest institutional shareholder is The Vanguard, holding a total of 4.04M shares, representing 5.10% of shares outstanding, with 3.38% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BVF Partners L.P.

6.29M

Coastlands Capital LP

4.76M

The Vanguard Group, Inc.

Star Investors

3.27M

-1.52%

RA Capital Management, LP

3.57M

BlackRock Institutional Trust Company, N.A.

3.13M

+7.28%

Invus Public Equities Advisors, LLC

2.07M

+200.33%

Zimmer Partners, LP

1.82M

+86.09%

Geode Capital Management, L.L.C.

1.37M

-1.08%

Wellington Management Company, LLP

1.28M

Sphera Funds Management Ltd.

1.28M

-34.67%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. No risk assessment score is currently available for Eledon Pharmaceuticals Inc. The Biotechnology & Medical Research industry's average is 3.38. The company's beta value is 0.91. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.